Other Information.
−Removed: On August 13, 2024, we issued a press release announcing our financial results for the quarter ended June 30, 2024.
+Added: Rostislav Raykov , a current member of our Board of Directors , adopted a trading arrangement on September 23, 2024 , which is intended to satisfy the Rule 10b5-1 affirmative defense.
+Added: This trading arrangement covers the disposition of up to 120,000 shares of the Company’s common shares, and will terminate on December 31, 2025 , unless earlier terminated in accordance with its terms.
+Added: No additional directors or officers informed us of the adoption, modification or termination of a “ Rule 10b5-1 trading arrangement” or “non- Rule 10b5-1 trading arrangement ,” as those terms are defined in Regulation S-K, Item 408.
+Added: On November 8, 2024, we issued a press release announcing our financial results for the quarter ended September 30, 2024.
A copy of the news release is attached to this Quarterly Report as Exhibit 99.1.
3 unchanged sentences
Certification of Chief Executive Officer and Chief Financial Officer of the Company in accordance with Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
−Removed: Press Release for Quarter Ended June 30, 2024 (filed herewith).
+Added: Press Release for Quarter Ended September 30, 2024 (filed herewith).
Inline XBRL Instance Document
8 unchanged sentences
Fennec Pharmaceuticals Inc.
−Removed: August 13, 2024
−Removed: /s/ Rostislav Raykov
−Removed: Rostislav Raykov
+Added: November 8, 2024
+Added: /s/ Jeff Hackman
Chief Executive Officer
(principal executive officer)
−Removed: August 13, 2024
+Added: November 8, 2024
/s/ Robert Andrade
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.